Efficacy and Safety of Zimlovisertib, Ritlecitinib, and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Journal:
Arthritis & Rheumatology
Published:
DOI:
10.1002/art.43184
Affiliations:
3
Authors:
12
Go to article
Institutions Authors Share
Pfizer, United States of America (USA)
10.000000
10.000000
 0.83
Samodzielny Publiczny Zespół Opieki Zdrowotnej w Kościanie (SPZOZ Kościan), Poland
1.000000
 0.08
Institute of Clinical Cardiology, Georgia
1.000000
 0.08
Interested in Clinical Sciences?